Phenom Recognized as a Strategic Leader in Fosway’s 2022 9-Grid™ for Talent Acquisition for Second Consecutive Year
4.5.2022 16:36:00 EEST | Business Wire | Press release
Phenom, the leading AI-powered talent experience platform, has been named a Strategic Leader in the 2022 Fosway 9-Grid™ for Talent Acquisition for the second year in a row. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. According to Fosway, Phenom has proven its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220503006092/en/
Phenom positioned as Strategic Leader in Fosway 9-Grid (Graphic: Business Wire)
With the highest job vacancy rate Europe has seen in 14 years, the talent shortage has developed into a crisis that extends far beyond human resources. To better connect with candidates and quickly fill open roles, CHROs and CEOs from today’s leading enterprises are choosing systems of intelligence to automate tasks and provide personalised experiences that job seekers expect in today’s competitive talent market.
Phenom’s position as a Strategic Leader reinforces that its Talent Experience Management (TXM) platform is enabling enterprises with the AI and automation necessary to quickly identify and hire best-fit talent, and an intelligent talent marketplace to develop and retain their best employees.
“Organisations are facing acute recruitment challenges that require innovative approaches to talent acquisition," said David Wilson, CEO, Fosway Group. "Phenom has consolidated its position as a Strategic Leader on the 2022 Fosway 9-Grid™ for Talent Acquisition through its focus on innovation and harnessing talent intelligence to deliver better recruitment outcomes for customers."
In 2021, 50,000 recruiters, talent marketers and hiring managers used Phenom to hire over 2 million people and engage over 5 million employees. Built on a vast network of data, contextual industry models and deep learning, the Phenom TXM platform is empowering organisations to:
- Engage & hire best-fit candidates faster: Connecting job seekers with relevant job recommendations and content based on skills, experience and location with a personalised Career Site, conversational Chatbot and CMS.
- Improve recruiter productivity: Identifying best-fit talent for open roles and automating tedious administrative tasks with a talent CRM, Campaigns, AI Scheduling, Video Assessments and AI Insights.
- Develop and retain employees: Fostering employee engagement, growth, and retention with an Internal Talent Marketplace, Career Pathing, Internal Mobility, Gigs, Diversity, Equity & Inclusion and Employee Resource Groups.
- Enable hiring managers: Streamlining collaboration with managers and elevating meaningful insights through talent analytics.
AXA, a global insurance company and Phenom customer, continues to see new value in the Phenom platform every day.
“With Phenom, it’s easier than ever for employees and candidates to explore open jobs across our organisation. Since the platform is constantly capturing and analyzing data, it’s delivering personalized experiences to help everyone find the right fit. When we’re able to connect people with opportunities where they can shape the way they work and realize their potential, that’s the greatest achievement of all,” said Amanda Vaughan, Global Head of Talent & Learning at AXA.
“As enterprises rely on talent experience to meet hiring demands in EMEA, maintaining our position as a Strategic Leader in Fosway’s Talent Acquisition grid signifies how we’re planting our roots in the HR technology market,” said Jeff Carey, senior vice president of international business at Phenom. “Our customers chose Phenom as the AI-powered solution to not only help them find candidates faster and retain talent today — they’re also investing in our constant innovation to ensure they’re future-proofed for the inevitable demands that will arise tomorrow.”
Companies across EMEA are successfully adopting Phenom’s talent experience platform to help candidates find the right job faster, recruiters discover best-fit talent, employees learn and evolve and managers build their teams. To support the growing need for Talent Experience Management, Phenom acquired three Europe-based companies and now has employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom.
To learn more about Phenom’s Strategic Leader position, please visit their blog.
To see Fosway’s full analysis, check out their 2022 9-grid™.
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalises and automates the talent journey for candidates, recruiters, employees and managers with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates find the right job, employees grow and evolve, recruiters discover top talent, and managers build teams faster. Phenom was a winner in the Business Intelligence Group’s 2021 Artificial Intelligence Excellence Awards program for its sophisticated machine learning capabilities and was ranked among the fastest-growing private companies in the 2021 Inc. 5000.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006092/en/
Contact information
Media:
Jennifer Lyons
Director, Global Communications
267-379-5066
jennifer.lyons@phenompeople.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom